Umbilical Cord Blood Transplants: Current Status and Evolving Therapies

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Hematopoietic cell transplants using stem cells from umbilical cord blood are used worldwide for the treatment of malignant and non-malignant disorders. Transplant procedures from this stem cell source have shown promising outcomes in successfully treating various hematologic, immunologic, malignant, and inherited metabolic disorders. Rapid availability of these stem cells is an important advantage over other unrelated donor transplants, especially in situations where waiting can adversely affect the prognosis. The umbilical cord blood is rich in CD34+ stem cells, though with a limited cell dose and usually takes longer to engraft. Limitations around this have been addressed by in vivo and ex vivo expansion techniques as well as enhanced engraftment kinetics. Development of adoptive immunotherapy using other components of umbilical cord blood such as regulatory T cells, virus-specific T cells, and natural killer cells has further transformed the field and enhanced the utility of umbilical cord blood unit.

Original languageEnglish (US)
Article number570282
JournalFrontiers in Pediatrics
StatePublished - Oct 2 2020

Bibliographical note

Publisher Copyright:
© Copyright © 2020 Gupta and Wagner.


  • alternative use of UCB
  • cord expansion
  • cord selection
  • immune effector function
  • umbical cord stem cells (UCSC)


Dive into the research topics of 'Umbilical Cord Blood Transplants: Current Status and Evolving Therapies'. Together they form a unique fingerprint.

Cite this